

Ad-hoc release according to section 15 Securities Trading Act (WpHG)

Dräger countering negative earnings trend by launching turnaround program

Lübeck – After a Supervisory Board meeting the Executive Board of Drägerwerk AG & Co. KGaA today approved a turnaround program. As a result the Executive Board is expecting a positive effect of EUR 100 million by 2011 against the benchmark figure of the net sales and cost structure in 2008 given comparable foreign exchange rates. The majority of the more than 400 individual measures are already to impact in 2010. For 2009 the Executive Board assumes that Group EBIT will be well below previous year figures and will although fall short of the EUR 97.5 million analysts' consensus figure. These negative impacts on earnings are attributable to an expected decline in net sales of around 5 percent and a shift in the product mix towards less profitable products. These effects will not be offset sufficiently by already available flexibility to adjust capacities and will not be completely compensated by the turnaround program. Despite the negative development trend in earnings, the Company will continue to maintain its R&D investments at high levels in line with the previous year and will be launching 13 new products in the medical division and 16 new products in the safety division.

Investor Relations:

Vanina Herbst
Tel. +49 451 882-2685
vanina.herbst@draeger.com

Corporate Communications:

Burkard Dillig
Tel. +49 451 882-2185
burkard.dillig@draeger.com

Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Deutschland
www.draeger.com